Thelansis’s "Hereditary Transthyretin Amyloidosis (hATTR) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Transthyretin Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Hereditary transthyretin amyloidosis (hATTR) is a rare inherited disorder in which mutations in the TTR gene cause misfolded transthyretin protein to accumulate as amyloid deposits in peripheral nerves and the heart, leading to progressive organ dysfunction. Current therapies either silence TTR production or stabilize the protein to reduce further amyloid formation, but they require lifelong treatment and do not correct the underlying genetic mutation. The most significant emerging advance is in vivo CRISPR gene editing, designed to permanently switch off the disease-causing gene with a single treatment, offering the possibility of a durable one-time therapy rather than ongoing disease management. Early studies have shown sustained reductions in TTR levels, and late-stage clinical trials are underway. For stakeholders, hATTR exemplifies the shift from managing the consequences of a mutation to targeting its source.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Hereditary Transthyretin Amyloidosis (hATTR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Hereditary Transthyretin Amyloidosis (hATTR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.